| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 148 | 2024 | 2542 | 8.570 |
Why?
|
| Estrogen Receptor alpha | 42 | 2024 | 454 | 5.980 |
Why?
|
| Receptors, Estrogen | 61 | 2024 | 796 | 4.220 |
Why?
|
| Drug Resistance, Neoplasm | 30 | 2024 | 745 | 3.090 |
Why?
|
| Tamoxifen | 29 | 2020 | 364 | 2.800 |
Why?
|
| Mutation | 35 | 2024 | 5965 | 1.860 |
Why?
|
| Molecular Targeted Therapy | 4 | 2021 | 379 | 1.690 |
Why?
|
| Heat-Shock Proteins | 19 | 2005 | 197 | 1.660 |
Why?
|
| Gene Expression Regulation, Neoplastic | 36 | 2020 | 1987 | 1.490 |
Why?
|
| Antineoplastic Agents, Hormonal | 18 | 2019 | 257 | 1.320 |
Why?
|
| Neoplasm Proteins | 15 | 2020 | 685 | 1.030 |
Why?
|
| Neoplasm Metastasis | 8 | 2021 | 711 | 0.990 |
Why?
|
| Receptors, Progesterone | 18 | 2012 | 877 | 0.970 |
Why?
|
| Estrogens | 15 | 2020 | 504 | 0.920 |
Why?
|
| Gene Expression Profiling | 12 | 2019 | 1789 | 0.850 |
Why?
|
| Cell Line, Tumor | 38 | 2024 | 3449 | 0.840 |
Why?
|
| Receptor, ErbB-2 | 11 | 2019 | 519 | 0.800 |
Why?
|
| Histone Deacetylases | 5 | 2014 | 115 | 0.790 |
Why?
|
| Receptors, Androgen | 5 | 2020 | 415 | 0.730 |
Why?
|
| Tumor Cells, Cultured | 34 | 2009 | 1064 | 0.720 |
Why?
|
| Promoter Regions, Genetic | 16 | 2014 | 1342 | 0.710 |
Why?
|
| Transcription, Genetic | 19 | 2020 | 1716 | 0.710 |
Why?
|
| Female | 117 | 2024 | 67333 | 0.670 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2020 | 131 | 0.670 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 1725 | 0.660 |
Why?
|
| Humans | 165 | 2024 | 126330 | 0.660 |
Why?
|
| Precision Medicine | 3 | 2021 | 325 | 0.640 |
Why?
|
| Estrogen Antagonists | 8 | 2011 | 103 | 0.630 |
Why?
|
| Estrogen Receptor beta | 8 | 2017 | 78 | 0.630 |
Why?
|
| Neoplasms, Hormone-Dependent | 11 | 2011 | 101 | 0.610 |
Why?
|
| Gene Regulatory Networks | 1 | 2021 | 369 | 0.610 |
Why?
|
| Repressor Proteins | 5 | 2014 | 833 | 0.600 |
Why?
|
| Signal Transduction | 23 | 2024 | 4638 | 0.580 |
Why?
|
| Estradiol | 11 | 2020 | 528 | 0.570 |
Why?
|
| Transcriptional Activation | 15 | 2018 | 483 | 0.560 |
Why?
|
| Sp1 Transcription Factor | 4 | 2012 | 44 | 0.550 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2009 | 243 | 0.540 |
Why?
|
| RNA, Messenger | 23 | 2018 | 2818 | 0.530 |
Why?
|
| Cell Proliferation | 17 | 2024 | 2394 | 0.520 |
Why?
|
| DNA, Neoplasm | 18 | 2015 | 305 | 0.490 |
Why?
|
| DNA-Binding Proteins | 12 | 2012 | 2071 | 0.480 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2024 | 558 | 0.480 |
Why?
|
| Aromatase Inhibitors | 5 | 2020 | 76 | 0.470 |
Why?
|
| Biomarkers, Tumor | 10 | 2024 | 1559 | 0.470 |
Why?
|
| ErbB Receptors | 2 | 2015 | 287 | 0.470 |
Why?
|
| Triple Negative Breast Neoplasms | 4 | 2024 | 242 | 0.460 |
Why?
|
| Genes, p53 | 5 | 2007 | 217 | 0.440 |
Why?
|
| Neoplasms | 3 | 2021 | 2807 | 0.440 |
Why?
|
| Protein Isoforms | 10 | 2013 | 403 | 0.430 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2018 | 1171 | 0.400 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 4 | 2009 | 1038 | 0.400 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 4 | 2019 | 1262 | 0.400 |
Why?
|
| Prognosis | 25 | 2019 | 4742 | 0.390 |
Why?
|
| Progesterone | 4 | 2009 | 621 | 0.390 |
Why?
|
| RNA, Neoplasm | 11 | 2013 | 138 | 0.390 |
Why?
|
| Transfection | 14 | 2009 | 1073 | 0.380 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2016 | 78 | 0.380 |
Why?
|
| Animals | 48 | 2024 | 34533 | 0.370 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2014 | 625 | 0.370 |
Why?
|
| Breast | 6 | 2016 | 212 | 0.370 |
Why?
|
| Polymerase Chain Reaction | 11 | 2012 | 1597 | 0.360 |
Why?
|
| Serine | 3 | 2018 | 176 | 0.350 |
Why?
|
| Mice, Nude | 13 | 2024 | 723 | 0.340 |
Why?
|
| Mice | 30 | 2024 | 17881 | 0.340 |
Why?
|
| Phosphorylation | 13 | 2024 | 1640 | 0.330 |
Why?
|
| MCF-7 Cells | 10 | 2024 | 224 | 0.330 |
Why?
|
| Neoplasm Invasiveness | 8 | 2016 | 625 | 0.330 |
Why?
|
| Leptin | 3 | 2020 | 214 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 7 | 2024 | 921 | 0.330 |
Why?
|
| Exons | 11 | 2000 | 808 | 0.330 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2009 | 86 | 0.320 |
Why?
|
| Precancerous Conditions | 4 | 2001 | 282 | 0.310 |
Why?
|
| Cell Movement | 8 | 2024 | 856 | 0.310 |
Why?
|
| Genetic Variation | 5 | 2013 | 1512 | 0.300 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2024 | 215 | 0.300 |
Why?
|
| Quinazolines | 3 | 2017 | 174 | 0.300 |
Why?
|
| Proto-Oncogene Proteins c-yes | 2 | 2005 | 3 | 0.300 |
Why?
|
| Transcription Factors | 10 | 2024 | 2618 | 0.290 |
Why?
|
| Nuclear Proteins | 5 | 2020 | 1280 | 0.290 |
Why?
|
| Protein Binding | 11 | 2020 | 1749 | 0.290 |
Why?
|
| Aromatase | 2 | 2020 | 22 | 0.280 |
Why?
|
| Lymphatic Metastasis | 11 | 2009 | 420 | 0.280 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2009 | 285 | 0.280 |
Why?
|
| Benzodioxoles | 1 | 2006 | 9 | 0.270 |
Why?
|
| Drug Resistance | 15 | 1995 | 257 | 0.270 |
Why?
|
| Genetic Markers | 3 | 2005 | 611 | 0.260 |
Why?
|
| Immunohistochemistry | 10 | 2016 | 1712 | 0.260 |
Why?
|
| Base Sequence | 18 | 2013 | 3118 | 0.260 |
Why?
|
| MAP Kinase Signaling System | 3 | 2018 | 315 | 0.260 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2018 | 260 | 0.250 |
Why?
|
| Heterogeneous-Nuclear Ribonucleoprotein D | 1 | 2005 | 4 | 0.250 |
Why?
|
| Mammary Glands, Animal | 1 | 2009 | 476 | 0.250 |
Why?
|
| Genetic Engineering | 1 | 2007 | 161 | 0.250 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 891 | 0.240 |
Why?
|
| Gene Amplification | 9 | 2019 | 236 | 0.240 |
Why?
|
| Antigens, Surface | 1 | 2005 | 118 | 0.240 |
Why?
|
| RNA Stability | 1 | 2005 | 82 | 0.240 |
Why?
|
| Molecular Sequence Data | 17 | 2013 | 3901 | 0.240 |
Why?
|
| src-Family Kinases | 2 | 2006 | 93 | 0.240 |
Why?
|
| 3' Untranslated Regions | 1 | 2005 | 165 | 0.240 |
Why?
|
| Apoptosis | 6 | 2024 | 1839 | 0.230 |
Why?
|
| Down-Regulation | 7 | 2016 | 689 | 0.230 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2024 | 18 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2024 | 44 | 0.230 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2024 | 59 | 0.220 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 430 | 0.220 |
Why?
|
| DNA | 9 | 2016 | 1621 | 0.220 |
Why?
|
| Doxorubicin | 4 | 2015 | 290 | 0.210 |
Why?
|
| BRCA1 Protein | 3 | 2009 | 71 | 0.210 |
Why?
|
| Pyridines | 2 | 2024 | 240 | 0.210 |
Why?
|
| Ligands | 7 | 2009 | 543 | 0.210 |
Why?
|
| Blotting, Western | 12 | 2010 | 1110 | 0.210 |
Why?
|
| Piperazines | 2 | 2024 | 242 | 0.200 |
Why?
|
| Gene Expression Regulation | 5 | 2002 | 2549 | 0.200 |
Why?
|
| Gene Expression | 7 | 2015 | 1560 | 0.200 |
Why?
|
| Mitochondria | 2 | 2021 | 696 | 0.200 |
Why?
|
| Carcinoma | 2 | 2012 | 290 | 0.200 |
Why?
|
| CRISPR-Cas Systems | 1 | 2024 | 259 | 0.190 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2024 | 569 | 0.190 |
Why?
|
| Nuclear Matrix-Associated Proteins | 2 | 2000 | 19 | 0.180 |
Why?
|
| Cell Division | 10 | 2000 | 762 | 0.180 |
Why?
|
| Matrix Attachment Region Binding Proteins | 2 | 2000 | 19 | 0.180 |
Why?
|
| RNA-Binding Proteins | 1 | 2005 | 579 | 0.180 |
Why?
|
| Response Elements | 3 | 2012 | 101 | 0.180 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2011 | 1300 | 0.180 |
Why?
|
| Cloning, Molecular | 6 | 1997 | 899 | 0.180 |
Why?
|
| Carcinoma, Lobular | 1 | 2001 | 24 | 0.180 |
Why?
|
| DNA Primers | 7 | 2007 | 659 | 0.180 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2019 | 76 | 0.180 |
Why?
|
| Binding Sites | 4 | 2009 | 1305 | 0.170 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2001 | 65 | 0.170 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 140 | 0.170 |
Why?
|
| RNA | 2 | 1996 | 578 | 0.170 |
Why?
|
| Up-Regulation | 3 | 2012 | 874 | 0.170 |
Why?
|
| Macrophage Activation | 1 | 2020 | 67 | 0.170 |
Why?
|
| Proportional Hazards Models | 5 | 2014 | 1380 | 0.170 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2020 | 44 | 0.160 |
Why?
|
| Phenotype | 13 | 2011 | 4323 | 0.160 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 255 | 0.160 |
Why?
|
| Transcriptome | 4 | 2014 | 1013 | 0.160 |
Why?
|
| Osteolysis | 1 | 1999 | 9 | 0.160 |
Why?
|
| Liquid Biopsy | 1 | 2019 | 14 | 0.160 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1999 | 23 | 0.160 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2014 | 298 | 0.160 |
Why?
|
| Acetylation | 5 | 2009 | 169 | 0.160 |
Why?
|
| HeLa Cells | 4 | 2009 | 796 | 0.160 |
Why?
|
| RNA Splicing | 6 | 2013 | 232 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2009 | 1685 | 0.160 |
Why?
|
| Gene Deletion | 4 | 2002 | 797 | 0.150 |
Why?
|
| Neoplastic Stem Cells | 2 | 2018 | 328 | 0.150 |
Why?
|
| Lysine | 3 | 2009 | 201 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 212 | 0.150 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 214 | 0.150 |
Why?
|
| Receptor, Notch4 | 1 | 2018 | 5 | 0.150 |
Why?
|
| rho Guanine Nucleotide Dissociation Inhibitor alpha | 2 | 2015 | 10 | 0.150 |
Why?
|
| Protein Array Analysis | 2 | 2016 | 102 | 0.150 |
Why?
|
| HSP27 Heat-Shock Proteins | 3 | 2005 | 7 | 0.140 |
Why?
|
| Cell Survival | 2 | 2018 | 835 | 0.140 |
Why?
|
| Receptor, Notch1 | 1 | 2018 | 66 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2012 | 210 | 0.140 |
Why?
|
| Time Factors | 5 | 2011 | 6334 | 0.140 |
Why?
|
| Quercetin | 1 | 1997 | 9 | 0.140 |
Why?
|
| Nuclear Matrix | 1 | 1997 | 21 | 0.140 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 3 | 2013 | 55 | 0.140 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2003 | 38 | 0.140 |
Why?
|
| Receptors, Somatomedin | 2 | 2016 | 25 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 4 | 2024 | 94 | 0.130 |
Why?
|
| Bone Development | 1 | 2017 | 58 | 0.130 |
Why?
|
| Bone Remodeling | 1 | 2017 | 55 | 0.130 |
Why?
|
| Molecular Chaperones | 3 | 2005 | 169 | 0.130 |
Why?
|
| Subtraction Technique | 1 | 1996 | 36 | 0.130 |
Why?
|
| Frozen Sections | 1 | 1996 | 26 | 0.130 |
Why?
|
| Selective Estrogen Receptor Modulators | 3 | 2012 | 60 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2016 | 15 | 0.130 |
Why?
|
| Immunoblotting | 3 | 2011 | 309 | 0.130 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2016 | 21 | 0.130 |
Why?
|
| Histone Deacetylase 1 | 3 | 2013 | 22 | 0.130 |
Why?
|
| Electrophoretic Mobility Shift Assay | 3 | 2011 | 49 | 0.130 |
Why?
|
| Membrane Glycoproteins | 6 | 2002 | 414 | 0.130 |
Why?
|
| Plasmids | 4 | 2011 | 514 | 0.130 |
Why?
|
| Receptors, CXCR4 | 2 | 2020 | 64 | 0.130 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2013 | 37 | 0.120 |
Why?
|
| Drug Design | 1 | 2016 | 156 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2016 | 103 | 0.120 |
Why?
|
| Thyroid Hormone Receptors beta | 1 | 2015 | 19 | 0.120 |
Why?
|
| Mi-2 Nucleosome Remodeling and Deacetylase Complex | 1 | 2014 | 13 | 0.120 |
Why?
|
| Disease Progression | 5 | 2014 | 2103 | 0.120 |
Why?
|
| DNA, Complementary | 4 | 2001 | 465 | 0.120 |
Why?
|
| Recombinant Fusion Proteins | 4 | 2009 | 771 | 0.110 |
Why?
|
| Patient Care Planning | 2 | 2005 | 122 | 0.110 |
Why?
|
| Trastuzumab | 3 | 2019 | 136 | 0.110 |
Why?
|
| Cytoskeleton | 1 | 2014 | 172 | 0.110 |
Why?
|
| Multivariate Analysis | 4 | 2007 | 1436 | 0.110 |
Why?
|
| Mutagenesis | 1 | 1994 | 343 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 342 | 0.100 |
Why?
|
| Oncogene Protein v-akt | 2 | 2011 | 31 | 0.100 |
Why?
|
| Catechin | 1 | 2013 | 13 | 0.100 |
Why?
|
| Middle Aged | 14 | 2017 | 27031 | 0.100 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2011 | 747 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 703 | 0.100 |
Why?
|
| RNA Precursors | 1 | 2013 | 64 | 0.100 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2005 | 394 | 0.100 |
Why?
|
| Adenocarcinoma | 4 | 2000 | 1029 | 0.090 |
Why?
|
| Hyperplasia | 3 | 2001 | 198 | 0.090 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2011 | 5 | 0.090 |
Why?
|
| Endothelin-1 | 1 | 2011 | 41 | 0.090 |
Why?
|
| Cell Adhesion | 2 | 2006 | 348 | 0.090 |
Why?
|
| CCAAT-Binding Factor | 1 | 2011 | 6 | 0.090 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 11 | 0.090 |
Why?
|
| Stilbenes | 1 | 2011 | 36 | 0.090 |
Why?
|
| Transcription Factor AP-1 | 3 | 2014 | 108 | 0.090 |
Why?
|
| Amino Acid Substitution | 2 | 2009 | 403 | 0.090 |
Why?
|
| Lactoferrin | 1 | 2011 | 78 | 0.090 |
Why?
|
| Cell Line | 8 | 2010 | 2734 | 0.090 |
Why?
|
| Ribonuclease III | 1 | 2011 | 93 | 0.090 |
Why?
|
| STAT3 Transcription Factor | 1 | 2012 | 219 | 0.090 |
Why?
|
| Genes, Reporter | 3 | 2009 | 382 | 0.090 |
Why?
|
| Cyclin D1 | 3 | 2011 | 115 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 3 | 2006 | 1006 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 132 | 0.090 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2011 | 190 | 0.090 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 1990 | 65 | 0.080 |
Why?
|
| Neoadjuvant Therapy | 3 | 2019 | 347 | 0.080 |
Why?
|
| Transcription Factor TFIIB | 1 | 2009 | 10 | 0.080 |
Why?
|
| Trefoil Factor-1 | 1 | 2009 | 7 | 0.080 |
Why?
|
| Radioligand Assay | 1 | 2009 | 26 | 0.080 |
Why?
|
| DNA Methylation | 1 | 2016 | 1073 | 0.080 |
Why?
|
| TATA-Box Binding Protein | 1 | 2009 | 30 | 0.080 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 27 | 0.080 |
Why?
|
| Genes, BRCA1 | 1 | 2009 | 50 | 0.080 |
Why?
|
| Point Mutation | 4 | 2002 | 350 | 0.080 |
Why?
|
| Sequence Deletion | 4 | 1996 | 530 | 0.080 |
Why?
|
| Co-Repressor Proteins | 1 | 2009 | 37 | 0.080 |
Why?
|
| Nuclear Receptor Coactivator 3 | 2 | 2009 | 348 | 0.080 |
Why?
|
| Neuregulin-1 | 1 | 2009 | 13 | 0.080 |
Why?
|
| Mammary Tumor Virus, Mouse | 1 | 2009 | 106 | 0.080 |
Why?
|
| Ovariectomy | 1 | 2009 | 181 | 0.080 |
Why?
|
| Adult | 10 | 2017 | 29802 | 0.080 |
Why?
|
| Tretinoin | 1 | 2009 | 114 | 0.080 |
Why?
|
| Genes, Neoplasm | 1 | 2009 | 82 | 0.080 |
Why?
|
| Models, Biological | 3 | 2009 | 1469 | 0.080 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 83 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2009 | 236 | 0.080 |
Why?
|
| Genome-Wide Association Study | 3 | 2013 | 1725 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2001 | 673 | 0.080 |
Why?
|
| Genes, Dominant | 2 | 2004 | 246 | 0.080 |
Why?
|
| Cricetinae | 5 | 2009 | 397 | 0.080 |
Why?
|
| Models, Genetic | 3 | 2016 | 764 | 0.070 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 187 | 0.070 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2009 | 203 | 0.070 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2011 | 379 | 0.070 |
Why?
|
| Luciferases | 2 | 2005 | 132 | 0.070 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2009 | 362 | 0.070 |
Why?
|
| Chromatin Immunoprecipitation | 3 | 2013 | 240 | 0.070 |
Why?
|
| Tumor Microenvironment | 2 | 2024 | 580 | 0.070 |
Why?
|
| Transplantation, Heterologous | 4 | 2011 | 260 | 0.070 |
Why?
|
| Risk | 1 | 2009 | 769 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2015 | 375 | 0.070 |
Why?
|
| Proteins | 3 | 1999 | 1043 | 0.070 |
Why?
|
| Cell Growth Processes | 1 | 2006 | 67 | 0.070 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 387 | 0.070 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2009 | 475 | 0.070 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2006 | 2 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2009 | 3203 | 0.070 |
Why?
|
| Drug Synergism | 1 | 2006 | 228 | 0.060 |
Why?
|
| ELAV-Like Protein 1 | 1 | 2005 | 8 | 0.060 |
Why?
|
| ELAV Proteins | 1 | 2005 | 14 | 0.060 |
Why?
|
| Uridine | 1 | 2005 | 34 | 0.060 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 1997 | 70 | 0.060 |
Why?
|
| Trans-Activators | 3 | 2005 | 807 | 0.060 |
Why?
|
| Fibroblasts | 2 | 2024 | 888 | 0.060 |
Why?
|
| Structure-Activity Relationship | 3 | 2000 | 580 | 0.060 |
Why?
|
| Adenine | 1 | 2005 | 117 | 0.060 |
Why?
|
| Glycoproteins | 1 | 1987 | 362 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 495 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2005 | 2194 | 0.060 |
Why?
|
| Upstream Stimulatory Factors | 1 | 2004 | 8 | 0.060 |
Why?
|
| Leucine Zippers | 1 | 2004 | 15 | 0.060 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2004 | 43 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 3 | 2011 | 566 | 0.060 |
Why?
|
| Dihydrotestosterone | 2 | 2020 | 67 | 0.060 |
Why?
|
| NIH 3T3 Cells | 1 | 2004 | 92 | 0.060 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2004 | 160 | 0.060 |
Why?
|
| Glutathione Transferase | 3 | 2001 | 157 | 0.060 |
Why?
|
| HLA-B Antigens | 1 | 2024 | 28 | 0.050 |
Why?
|
| Antigen Presentation | 1 | 2024 | 106 | 0.050 |
Why?
|
| Aged | 9 | 2017 | 19962 | 0.050 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 2428 | 0.050 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 2 | 2012 | 163 | 0.050 |
Why?
|
| Blotting, Southern | 6 | 1997 | 217 | 0.050 |
Why?
|
| Stromal Cells | 2 | 2017 | 305 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2003 | 33 | 0.050 |
Why?
|
| Histone Acetyltransferases | 2 | 2020 | 312 | 0.050 |
Why?
|
| Sp3 Transcription Factor | 1 | 2002 | 7 | 0.050 |
Why?
|
| Loss of Heterozygosity | 2 | 2001 | 132 | 0.050 |
Why?
|
| Rats | 1 | 2009 | 3763 | 0.050 |
Why?
|
| SUMO-1 Protein | 1 | 2002 | 8 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2005 | 560 | 0.050 |
Why?
|
| MAP Kinase Kinase Kinase 1 | 1 | 2002 | 15 | 0.050 |
Why?
|
| Cathepsin D | 2 | 2010 | 17 | 0.050 |
Why?
|
| Nitriles | 2 | 2014 | 146 | 0.050 |
Why?
|
| RNA Polymerase II | 2 | 2013 | 100 | 0.050 |
Why?
|
| Chromatin | 2 | 2005 | 578 | 0.050 |
Why?
|
| Triazoles | 2 | 2014 | 140 | 0.050 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 546 | 0.050 |
Why?
|
| Interdisciplinary Communication | 1 | 2003 | 131 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-fos | 2 | 2014 | 59 | 0.050 |
Why?
|
| Cell Differentiation | 1 | 2009 | 1931 | 0.050 |
Why?
|
| Peptides | 2 | 2024 | 820 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2024 | 347 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2014 | 631 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 2 | 1994 | 96 | 0.050 |
Why?
|
| Epidermal Growth Factor | 2 | 2012 | 122 | 0.040 |
Why?
|
| Proto-Oncogenes | 2 | 1991 | 34 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 3 | 2000 | 1026 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2011 | 93 | 0.040 |
Why?
|
| Pregnancy | 2 | 2009 | 7257 | 0.040 |
Why?
|
| Polymorphism, Restriction Fragment Length | 2 | 1991 | 148 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2024 | 482 | 0.040 |
Why?
|
| Genes | 2 | 1992 | 446 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2011 | 198 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 2 | 2013 | 386 | 0.040 |
Why?
|
| Osteosarcoma | 2 | 2000 | 255 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2012 | 343 | 0.040 |
Why?
|
| COS Cells | 3 | 2010 | 277 | 0.040 |
Why?
|
| Molecular Conformation | 1 | 2020 | 107 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2007 | 12380 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 2068 | 0.040 |
Why?
|
| Macromolecular Substances | 2 | 2000 | 182 | 0.040 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 1999 | 9 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 1999 | 19 | 0.040 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2020 | 87 | 0.040 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1999 | 15 | 0.040 |
Why?
|
| Survival Analysis | 4 | 2016 | 1517 | 0.040 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 56 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-jun | 2 | 2014 | 36 | 0.040 |
Why?
|
| Molecular Probe Techniques | 1 | 1999 | 23 | 0.040 |
Why?
|
| Somatomedins | 2 | 1989 | 37 | 0.040 |
Why?
|
| Amino Acid Sequence | 5 | 2001 | 2719 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1999 | 102 | 0.040 |
Why?
|
| Clone Cells | 1 | 1999 | 169 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2007 | 3777 | 0.040 |
Why?
|
| Melanoma | 2 | 1998 | 942 | 0.040 |
Why?
|
| Isoenzymes | 1 | 1999 | 228 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 177 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 297 | 0.040 |
Why?
|
| Rhabdomyosarcoma | 1 | 2001 | 193 | 0.040 |
Why?
|
| RNA, Small Interfering | 2 | 2011 | 677 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2018 | 60 | 0.040 |
Why?
|
| Actins | 2 | 1990 | 340 | 0.040 |
Why?
|
| Polymorphism, Genetic | 3 | 1993 | 820 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2011 | 469 | 0.040 |
Why?
|
| Heat Shock Transcription Factors | 1 | 1997 | 19 | 0.040 |
Why?
|
| Drosophila | 1 | 2002 | 792 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 1995 | 472 | 0.040 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 779 | 0.030 |
Why?
|
| Autocrine Communication | 1 | 1997 | 28 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1998 | 83 | 0.030 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 1997 | 70 | 0.030 |
Why?
|
| Pilot Projects | 2 | 1999 | 1413 | 0.030 |
Why?
|
| Protein Domains | 1 | 2018 | 231 | 0.030 |
Why?
|
| Superoxide Dismutase | 2 | 2012 | 180 | 0.030 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 306 | 0.030 |
Why?
|
| Osteoclasts | 1 | 2017 | 56 | 0.030 |
Why?
|
| Antigens, Neoplasm | 1 | 1999 | 384 | 0.030 |
Why?
|
| Air | 1 | 1996 | 25 | 0.030 |
Why?
|
| Desiccation | 1 | 1996 | 45 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2010 | 65 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 1996 | 37 | 0.030 |
Why?
|
| Transcription Factor AP-2 | 1 | 1996 | 22 | 0.030 |
Why?
|
| DNA Transposable Elements | 1 | 1997 | 183 | 0.030 |
Why?
|
| Cervix Uteri | 1 | 1996 | 63 | 0.030 |
Why?
|
| Translocation, Genetic | 1 | 2018 | 359 | 0.030 |
Why?
|
| Osteoblasts | 1 | 2017 | 151 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 642 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 1996 | 123 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2000 | 828 | 0.030 |
Why?
|
| S Phase | 1 | 1995 | 74 | 0.030 |
Why?
|
| Taxoids | 1 | 2015 | 68 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1998 | 656 | 0.030 |
Why?
|
| Estrogen Receptor Antagonists | 1 | 2014 | 4 | 0.030 |
Why?
|
| Androstenedione | 1 | 2014 | 11 | 0.030 |
Why?
|
| Chromosome Aberrations | 2 | 1995 | 616 | 0.030 |
Why?
|
| Proteomics | 1 | 2018 | 513 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1996 | 357 | 0.030 |
Why?
|
| Male | 5 | 2011 | 62031 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 1994 | 99 | 0.030 |
Why?
|
| Lymph Nodes | 1 | 1995 | 380 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 1994 | 117 | 0.030 |
Why?
|
| Hot Temperature | 1 | 1994 | 140 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 515 | 0.030 |
Why?
|
| Tea | 1 | 2013 | 16 | 0.030 |
Why?
|
| Regression Analysis | 1 | 1995 | 784 | 0.030 |
Why?
|
| Endometrial Neoplasms | 1 | 1994 | 99 | 0.030 |
Why?
|
| Antibodies | 1 | 1994 | 370 | 0.030 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 1 | 2012 | 17 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 1997 | 3040 | 0.020 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2012 | 50 | 0.020 |
Why?
|
| Recombinant Proteins | 2 | 1998 | 1399 | 0.020 |
Why?
|
| Sumoylation | 1 | 2012 | 37 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 106 | 0.020 |
Why?
|
| Bone and Bones | 1 | 1994 | 271 | 0.020 |
Why?
|
| Receptors, Leptin | 1 | 2012 | 40 | 0.020 |
Why?
|
| Receptor, Endothelin A | 1 | 2011 | 13 | 0.020 |
Why?
|
| Endothelin A Receptor Antagonists | 1 | 2011 | 8 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 1992 | 137 | 0.020 |
Why?
|
| Incidence | 1 | 1999 | 3170 | 0.020 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 1991 | 5 | 0.020 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1991 | 50 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2011 | 15 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2011 | 94 | 0.020 |
Why?
|
| Casein Kinase II | 1 | 2011 | 14 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 1073 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2018 | 1021 | 0.020 |
Why?
|
| rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 8 | 0.020 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 2011 | 75 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2011 | 16517 | 0.020 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2011 | 13 | 0.020 |
Why?
|
| Ki-67 Antigen | 1 | 2011 | 115 | 0.020 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2011 | 36 | 0.020 |
Why?
|
| Isoxazoles | 1 | 2011 | 24 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 1994 | 356 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 734 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 126 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 1995 | 1291 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 508 | 0.020 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 102 | 0.020 |
Why?
|
| Alleles | 2 | 2013 | 1625 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 1994 | 1089 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2011 | 68 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 264 | 0.020 |
Why?
|
| RNA Interference | 1 | 2012 | 512 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2011 | 243 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 442 | 0.020 |
Why?
|
| Receptor Cross-Talk | 1 | 2010 | 37 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 5204 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2010 | 81 | 0.020 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1989 | 42 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2009 | 31 | 0.020 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2010 | 109 | 0.020 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2009 | 46 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 215 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2012 | 499 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 595 | 0.020 |
Why?
|
| Cricetulus | 1 | 2009 | 93 | 0.020 |
Why?
|
| Tyrosine | 1 | 2009 | 150 | 0.020 |
Why?
|
| CHO Cells | 1 | 2009 | 163 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2009 | 84 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 209 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 1994 | 1111 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1989 | 124 | 0.020 |
Why?
|
| Ubiquitination | 1 | 2009 | 170 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2011 | 612 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 2 | 2001 | 765 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 1989 | 109 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2010 | 353 | 0.020 |
Why?
|
| Transforming Growth Factors | 1 | 1988 | 21 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 318 | 0.020 |
Why?
|
| Multigene Family | 1 | 1989 | 302 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 248 | 0.020 |
Why?
|
| X Chromosome | 1 | 1989 | 338 | 0.020 |
Why?
|
| Computational Biology | 1 | 2013 | 838 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2011 | 1266 | 0.020 |
Why?
|
| Receptors, Cell Surface | 1 | 1989 | 480 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2013 | 902 | 0.020 |
Why?
|
| Placenta | 1 | 1991 | 513 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2001 | 664 | 0.020 |
Why?
|
| Carcinoma in Situ | 2 | 2001 | 70 | 0.020 |
Why?
|
| Arginine | 1 | 2009 | 337 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 2594 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 1993 | 1768 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 1997 | 1668 | 0.020 |
Why?
|
| Disease Models, Animal | 2 | 2011 | 4467 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2005 | 62 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2009 | 913 | 0.010 |
Why?
|
| Genomics | 1 | 2013 | 1538 | 0.010 |
Why?
|
| Mutation, Missense | 1 | 2009 | 881 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 2689 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 2 | 2006 | 4466 | 0.010 |
Why?
|
| Genes, erbB-2 | 1 | 2003 | 37 | 0.010 |
Why?
|
| Cytoprotection | 1 | 2003 | 38 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2003 | 89 | 0.010 |
Why?
|
| Phytotherapy | 1 | 2003 | 50 | 0.010 |
Why?
|
| Hydrolysis | 1 | 2003 | 161 | 0.010 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 23 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 143 | 0.010 |
Why?
|
| Protease Inhibitors | 1 | 2003 | 96 | 0.010 |
Why?
|
| Hydroxamic Acids | 1 | 2002 | 57 | 0.010 |
Why?
|
| Smad3 Protein | 1 | 2002 | 58 | 0.010 |
Why?
|
| Amino Acid Motifs | 1 | 2002 | 194 | 0.010 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2003 | 369 | 0.010 |
Why?
|
| Growth Substances | 1 | 2001 | 114 | 0.010 |
Why?
|
| Receptors, Steroid | 1 | 2003 | 275 | 0.010 |
Why?
|
| Analysis of Variance | 2 | 1994 | 1020 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 156 | 0.010 |
Why?
|
| Recurrence | 2 | 1996 | 1400 | 0.010 |
Why?
|
| Research | 1 | 2003 | 265 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 79 | 0.010 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2001 | 91 | 0.010 |
Why?
|
| Hybridomas | 1 | 2000 | 41 | 0.010 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2000 | 43 | 0.010 |
Why?
|
| G1 Phase | 1 | 2001 | 66 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2002 | 973 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 95 | 0.010 |
Why?
|
| Prostatic Neoplasms | 1 | 2009 | 1551 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2000 | 90 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2001 | 393 | 0.010 |
Why?
|
| Gene Library | 1 | 2001 | 218 | 0.010 |
Why?
|
| Antibody Specificity | 1 | 2000 | 203 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 2000 | 43 | 0.010 |
Why?
|
| Cross Reactions | 1 | 2000 | 191 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 2000 | 290 | 0.010 |
Why?
|
| Mitotic Index | 1 | 1999 | 18 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2006 | 2900 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2003 | 1251 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 683 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2002 | 592 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2001 | 364 | 0.010 |
Why?
|
| Survival Rate | 2 | 1994 | 2070 | 0.010 |
Why?
|
| Heat Stress Disorders | 1 | 1998 | 10 | 0.010 |
Why?
|
| Aged, 80 and over | 3 | 1996 | 6645 | 0.010 |
Why?
|
| Breast Diseases | 1 | 1998 | 35 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1998 | 70 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2000 | 782 | 0.010 |
Why?
|
| Cytokines | 1 | 2003 | 1306 | 0.010 |
Why?
|
| Heterozygote | 1 | 1998 | 674 | 0.010 |
Why?
|
| Metaphase | 1 | 1995 | 33 | 0.010 |
Why?
|
| Ribonucleases | 1 | 1995 | 51 | 0.010 |
Why?
|
| GRB7 Adaptor Protein | 1 | 1994 | 2 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1994 | 119 | 0.010 |
Why?
|
| Gene Dosage | 1 | 1995 | 447 | 0.010 |
Why?
|
| Biopsy | 1 | 1997 | 1257 | 0.010 |
Why?
|
| Axilla | 1 | 1993 | 39 | 0.010 |
Why?
|
| Codon | 1 | 1993 | 99 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1995 | 589 | 0.010 |
Why?
|
| Genome | 1 | 1995 | 482 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1993 | 74 | 0.010 |
Why?
|
| Caenorhabditis elegans | 1 | 1994 | 231 | 0.010 |
Why?
|
| Nucleic Acid Conformation | 1 | 1993 | 188 | 0.010 |
Why?
|
| Postmenopause | 1 | 1993 | 129 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 1993 | 183 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2000 | 949 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 1993 | 371 | 0.010 |
Why?
|
| Immune Sera | 1 | 1990 | 92 | 0.010 |
Why?
|
| Cell Aggregation | 1 | 1990 | 24 | 0.010 |
Why?
|
| Culture Techniques | 1 | 1990 | 82 | 0.010 |
Why?
|
| Colchicine | 1 | 1990 | 38 | 0.010 |
Why?
|
| Vinblastine | 1 | 1990 | 55 | 0.010 |
Why?
|
| Menopause | 1 | 1990 | 75 | 0.010 |
Why?
|
| Methylation | 1 | 1990 | 225 | 0.010 |
Why?
|
| Electrophoresis | 1 | 1989 | 50 | 0.010 |
Why?
|
| Binding, Competitive | 1 | 1989 | 193 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2000 | 1334 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1989 | 266 | 0.000 |
Why?
|
| Hybrid Cells | 1 | 1989 | 79 | 0.000 |
Why?
|
| DNA Restriction Enzymes | 1 | 1989 | 122 | 0.000 |
Why?
|
| DNA Probes | 1 | 1989 | 124 | 0.000 |
Why?
|
| Hormones | 1 | 1989 | 189 | 0.000 |
Why?
|
| Chromatography, Affinity | 1 | 1988 | 70 | 0.000 |
Why?
|
| Kinetics | 1 | 1990 | 1325 | 0.000 |
Why?
|
| DNA Replication | 1 | 1989 | 352 | 0.000 |
Why?
|
| Leukocytes | 1 | 1989 | 213 | 0.000 |
Why?
|
| Rabbits | 1 | 1988 | 719 | 0.000 |
Why?
|
| Risk Factors | 1 | 1991 | 10375 | 0.000 |
Why?
|